PUBLIC HEALTH FOUNDATION OF INDIA

Their core work

The Public Health Foundation of India (PHFI) is India's leading public health research and policy institution, conducting applied research at the intersection of epidemiology, health systems, and evidence-based policy. Their H2020 work positions them as a bridge between European research consortia and India's large, diverse population — providing access to clinical trial cohorts, immune profiling data, and health economics expertise across a 1.4 billion-person context that no European partner can replicate. In INCENTIVE, they contribute to next-generation influenza vaccine development through human challenge studies and immune monitoring, while their earlier PROTECTED involvement brought South Asian population data to the study of endocrine disruptor exposure and health effects. For external collaborators, PHFI's core value is translating scientific findings into real-world public health relevance, especially for low- and middle-income country contexts.

What they specialise in

How they've shifted over time

PHFI entered H2020 through PROTECTED (2017-2021), contributing to environmental and chemical health research on endocrine disruptors — a passive partner role with no recorded keywords, suggesting a supporting data or advisory function rather than technical leadership. By 2020, their profile shifted sharply toward infectious disease and vaccine innovation, with INCENTIVE (2020-2026) generating a dense cluster of clinical research keywords: immune profiling, human challenge studies, preclinical validation, and health economics. The trajectory is clear: from broad environmental health participation to focused, technically specific vaccine research where PHFI appears to play a more substantive scientific role.

PHFI is moving toward becoming a specialized clinical research partner for Indo-European infectious disease and vaccine development projects, with increasing technical depth in immune monitoring and human trial design.

How they like to work

PHFI consistently joins as a partner or participant rather than leading projects — they have never coordinated an H2020 project. Their consortia tend to be large (32 unique partners across 11 countries), which reflects their participation in ambitious multi-partner frameworks like INCENTIVE. This pattern suggests they are brought in specifically for their Indian population access and public health expertise, rather than as a generalist contributor, making them a reliable specialist node rather than a coordination hub.

PHFI has connected with 32 unique consortium partners across 11 countries through just two projects, reflecting the large multi-partner nature of both PROTECTED and INCENTIVE. Their network is Indo-European by design, bridging South Asian institutions and populations with EU research teams.

What sets them apart

PHFI is the rare H2020 partner that brings access to India's population at scale — clinical trial recruitment, disease burden data, and immune response profiling in a context that is epidemiologically distinct from European cohorts. For vaccine or environmental health research requiring non-European validation or a low-to-middle-income country dimension, PHFI fills a gap that no European institution can. Their dual competence in research execution and health policy translation also makes them valuable when a consortium needs findings to reach national health system decision-makers in South Asia.

Highlights from their portfolio

• INCENTIVE
  A 2020-2026 Indo-European consortium for next-generation influenza vaccine innovation, spanning the full development pipeline from preclinical validation through human challenge trials — PHFI's most technically substantive and longest H2020 engagement.
• PROTECTED
  An early cross-disciplinary project on endocrine disruptor detection and health risk assessment, demonstrating PHFI's ability to contribute to European environmental health research with South Asian population perspectives.